How Much Does Tirzepatide Cost?

No — there is no FDA-approved generic tirzepatide, so any price you see advertised for one is not what it claims to be. Tirzepatide is under patent into the 2030s, and a generic can only exist after those expire and a manufacturer wins FDA approval for an equivalent. What is actually sold under names like "generic tirzepatide" is compounded tirzepatide, which is a different legal category: a generic is an FDA-approved equivalent of the brand, while a compounded preparation has not been through FDA review for safety, quality or consistency at all. The price gap is real — compounded runs far below brand — but you are not buying a generic, and it is worth knowing which one you are being sold.

It depends on the route. Brand Mounjaro and Zepbound carry list (WAC) prices of about $1,069/mo and $1,086/mo before insurance. Lilly's own self-pay price is $299/mo at the 2.5 mg starting dose, then $449/mo at maintenance if you refill within 45 days — or up to $699/mo if you don't, and compounded tirzepatide runs $99–$450/mo — though compounded is not FDA-approved as a finished drug. With commercial insurance and a manufacturer savings card, brand copays can drop to as low as $25/month. Prices as of July 2026.

Lilly sells Zepbound direct for cash, well below the ~$1,086/month list price — but it is not one price, and the cheaper one has a condition almost nobody mentions. Lilly's regular self-pay prices are $299 at 2.5 mg, $399 at 5 mg, $499 at 7.5 mg, and $699 at 10, 12.5 and 15 mg. A purchase offer brings 7.5 mg and up down to $449 — but only if you buy each refill within 45 days of the previous fill's delivery. Refill late once and you pay the regular price: on a maintenance dose that is a $250/month jump. Budget for the top of the ladder, not the bottom — 2.5 mg is a starting dose and is not approved for maintenance.

On sticker price, often yes — compounded tirzepatide runs about $99–$450/mo, comparable to or below LillyDirect self-pay vials. But it is not FDA-approved as a finished product, quality varies by pharmacy, and the FDA removed tirzepatide from its shortage list in October 2024, which narrowed the legal basis for large-scale compounding. Verify any pharmacy is a licensed US 503A/503B, and factor in visit or membership fees.

Coverage is plan-specific. Commercial plans commonly cover Mounjaro for type 2 diabetes (with prior authorization) and increasingly cover Zepbound for weight management, though self-funded employer plans often exclude weight-loss drugs. Medicare covers tirzepatide for approved medical indications (like diabetes, or the Zepbound obstructive-sleep-apnea indication) but not for weight loss alone. Check your formulary and our payer coverage pages.

Without insurance, Lilly's own self-pay pricing ($299/mo at the 2.5 mg starting dose, then $449/mo at maintenance if you refill within 45 days — or up to $699/mo if you don't) is the cheapest FDA-approved route; compounded tirzepatide can be lower but is not FDA-approved. With commercial insurance, a savings card can bring the brand copay to as low as $25/month. See our full cheapest-tirzepatide breakdown for the route-by-route ranking.